Nyrada Inc

Nyrada Inc, located in Gordon, New South Wales, is a preclinical stage drug development company focused on creating novel small molecule drugs that target underlying pathological processes in cardiovascular, neurodegenerative, and chronic inflammatory diseases. With a mission to become a high-growth biopharmaceutical entity, the company emphasizes drug discovery and early-stage development, particularly in areas with significant unmet clinical needs.

The organization currently manages four drug development programs, including a PCSK9 inhibitor for high LDL cholesterol treatment, a neuroprotectant for ischaemic stroke and traumatic brain injury, a drug addressing pain from peripheral nerve damage, and another aimed at treating autoimmune diseases like psoriasis. Nyrada's innovative approach centers around the benzopyran molecular scaffold, aiming to deliver effective and well-tolerated therapies where few alternatives exist.

Generated from the website